Slate Medicines | $130,000,000 | (Feb 25, 2026)
Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Ridge Bio
United States
- Palo Alto, CA
- 10/09/2025
- Seed
- $25,000,000
Ridge Biotechnologies is pioneering AI-based enzyme and targeted drug design to power the next wave of precision therapeutics.
Led by a collection of established biotech entrepreneurs and faculty from top institutions, we use proprietary machine learning models informed by high-throughput cell-free experimentation for a wide range of applications in antibody-drug conjugates (ADCs), conditionally active prodrugs, in vivo CART therapies, targeted nucleic acid delivery, radiotherapies, and enzyme-based therapeutics.
Our current product lines include NativeLink enzymes that enable precision bioconjugation including construction of ADCs and Antibody-oligonucleotide conjugates, ProTrigger linkers that provide tissue and disease-specific activation and release of diverse payloads and prodrugs, and new classes of enzyme-based Catalytic Medicines.
We are focused on enabling our partners to build better drugs for patients.
- Industry Biotechnology Research
- Website https://ridgebio.com/
- LinkedIn https://www.linkedin.com/company/ridge-bio/
KrisAtWork | $3,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)